It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Intensity-modulated radiation therapy, when used in the clinic, prolongs fraction delivery time. Here we investigated both the in vivoand in vitroradiobiological effects on the A549 cell line, including the effect of different delivery times with the same dose on A549 tumor growth in nude mice. The in vitroeffects were studied with clonogenic assays, using linear-quadratic and incomplete repair models to fit the dose-survival curves. Fractionated irradiation of different doses was given at one fraction per day, simulating a clinical dose-time-fractionation pattern. The longer the interval between the exposures, the more cells survived. To investigate the in vivoeffect, we used sixty-four nude mice implanted with A549 cells in the back legs, randomly assigned into eight groups. A 15 Gy radiation dose was divided into different subfractions. The maximum and minimum tumor diameters were recorded to determine tumor growth. Tumor growth was delayed for groups with prolonged delivery time (40 min) compared to the group receiving a single dose of 15 Gy (P< 0.05), and tumors with a 20 min delivery time had delayed growth compared to those with a 40 min delivery time [20′ (7.5 Gy × 2 F) vs 40′ (7.5 Gy × 2 F), P= 0.035; 20′ (3 Gy × 5 F) vs 40′ (3 Gy × 5 F); P= 0.054; 20′ (1.67 Gy × 9 F) vs 40′ (1.67 Gy × 9 F), P= 0.028]. A prolonged delivery time decreased the radiobiological effects, so we strongly recommend keeping the delivery time as short as possible.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Radiation Oncology, Fudan University Shanghai Cancer Center, No. 270, Dong-An Rd., Shanghai, China, 200032; Department of Oncology, Shanghai Medical College, Fudan University, No. 270, Dong-An Rd., Shanghai, China, 200032; Department of Medical Oncology, Xu-Hui Center Hospital, No. 966, Huai-Hai Middle Rd., Shanghai, China, 200031
2 Department of Nuclear Medicine, Ren-Ji Hospital, Shanghai Jiaotong University, No.1630, Dong-Fang Rd., Shanghai, China, 200127
3 Department of Radiation Oncology, Fudan University Shanghai Cancer Center, No. 270, Dong-An Rd., Shanghai, China, 200032; Department of Oncology, Shanghai Medical College, Fudan University, No. 270, Dong-An Rd., Shanghai, China, 200032
4 Department of Oncology, Shanghai Medical College, Fudan University, No. 270, Dong-An Rd., Shanghai, China, 200032; Breast Cancer Center, Fudan University Shanghai Cancer Center, No. 270, Dong-An Rd., Shanghai, China, 200032